Campylobacter fetus ssp. fetus strains causing systemic infections in humans are highly resistant to normal and immune serum, which is due to the presence of high molecular weight (100,000, 127,000, or 149,000) surface (S-layer) proteins. Using serum-resistant parental strains (8240 LP and 23D) containing the 100,000-mol wt protein and serum-sensitive mutants (8240 HP and 23B) differing only in that they lack the 100,000-mol wt protein capsule, we examined complement binding and activation, and opsono-phagocytosis by polymorphonuclear leukocytes. C3 consumption was similar for all four strains but C3 was not efficiently bound to 82-40 LP or 23D even in the presence of immune serum, and the small amount of C3 bound was predominently the hemolytically inactive iC3b fragment. Consumption and binding of C5 and C9 was significantly greater for the unencapsulated than the encapsulated strains. Opsonization of 8240 HP with heat-inactivated normal human serum caused > 99% killing by human PMN. Similar opsonization of 82-40 LP showed no kill, but use of immune serum restored killing. Findings in a PMN chemiluminescence assay showed parallel results. Association of 32P-labeled 82-40 HP with PMN in the presence of HINHS was 19-fold that for the 8240 LP, and electron microscopy illustrated that the difference was in uptake rather than in binding. These results indicate that presence of the 100,000-mol wt protein capsule on the surface of C. fetus leads to impaired C3b binding, thus explaining serum resistance and defective opsonization in NHS, mechanisms that explain the capacity of this enteric organism to cause systemic infections.
strains of C. fetus that had lost their serum resistance. These strains, 82-40 HP and 23-B, lacked a 100,000-mol wt surface (S-layer) protein but were otherwise identical to the parent strains (82-40 LP and 23D) (7) . Strain 23D but not 23B had an S-layer microcapsule identified by electron microscopy; this microcapsule was composed of a 100,000-mol wt protein (8, 9) .
In the present investigation, we have used our paired strains (82-40 LP and 82-40 HP, 23D and 23B) to help elucidate the molecular basis for the serum resistance of encapsulated C. fetus. However, serum resistance, while probably an important virulence factor for C.fetus, and probably necessary for extraintestinal spread, may not be sufficient to explain disease (5) . Since many of the persons affected are immunocompromised or have white blood cell dysfunction (2, 3, 7, 10) , we also examined the uptake and killing of our paired C. fetus strains by human PMN. In the studies we report, we found virtually no binding of C3b to the encapsulated C. fetus strains, a phenomenon that explains the observed serum resistance and resistance to phagocytosis except in the presence of immune serum.
Methods
Media. Media included Medium 199 with Hank's balanced salt solution (HBSS, pH 7.4, Gibco, Grand Island, NY); HBSS with 1% gelatin (Hank's gel); trypticase soy agar with 5% sheep blood (BAP,' Pasco Laboratories, Wheat Ridge, CO); phosphate-buffered saline (PBS, pH 7.4).
Bacteria. All human Campylobacter isolates were from the Denver Campylobacter laboratory culture collection as previously described (6, 7) . Typical serum-resistant C.fetus strains and their laboratory-derived mutants were studied (Table I) . Bacteria had been frozen at -70'C and had six or fewer passages on artificial media before use in these studies. Strains were cultured on typticase soy agar with 5% sheep erythrocytes (BAP), and incubated for 24-48 h at 37°C for C.fetus in a microaerobic atmosphere as previously described (6) . C. jejuni strains were incubated at 42°C but otherwise treated as above. SDS-PAGE of solubilized whole cells was performed as previously described (11) . Staphylococcus aureus 502A and a serum-sensitive Escherichia coli K12 strain were used as controls for the complement-consumption and phagocytosis experiments. Serum. Pooled normal human serum (NHS) was collected from three to five normal volunteers without any known history of C. fetus infection. Rabbits were immunized with encapsulated or unencapsulated C. fetus strains as previously described (12) . Specificities of the antisera were defined by immunoblot and radioimmunoprecipitation as previously described (7, 13) . Titers of the immune rabbit sera to homologous organisms in an ELISA (14) to detect IgG to C. fetus 1. Abbreviations used in this paper: BAP, trypticase soy agar with 5% sheep blood plate; HINHS, heated-inactived normal human serum; NHS, normal human serum; SDW, sterile distilled water. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] determinations. * Serotyping performed as previously described (11) . I By SDS-PAGE and radioiodination as described (6). 1 As described in references 8 and 9.
always were greater than 1:3,200. Aliquots of NHS, normal rabbit serum, or immune rabbit serum were heated at 560C for 30 min to block complement activation. For use in some experiments, 2.0 ml of immune rabbit serum to 82-40 LP were absorbed six times with -1010 82-40 LP CFU for 60 min at 370C, and the bacteria were removed by centrifugation at 12,000 g for 10 min. All sera were stored at -70'C until used in the assays. Serum bactericidal assay. The susceptibility of the C. fetus and C. jejuni strains to the bactericidal activity present in NHS was assessed in a standardized assay, as previously described (6) . In brief, 24-h cell cultures were diluted in Medium 199 with HBSS to concentrations of 103 to 10' CFU/ml, then incubated for 60 min at 370C with 10% pooled serum from healthy adults. Pre-and postincubation viable colony counts were compared in order to calculate loglo killing. On the basis of our previous study (6) , serum sensitivity was defined as 2 1.0 log1o (90%) killing, resistance as < 0.1 log10 killing, and intermediate, between these two values; all strains were tested at least in duplicate.
Consumption of hemolytic complement activity. Consumption of total hemolytic complement activity was measured in reaction mixtures of 100% pooled NHS containing 109 CFU/ml of serum-sensitive or serum-resistant organisms harvested and then pelleted from 24-h cultures on BAP plates incubated at the temperature optimum for that strain. Hemolytic titrations on reaction mixture supernatants were performed after incubation at 370C for 30 or 60 min. The standard hemolytic assay using sheep erythrocytes and rabbit serum was performed as described previously (6) . Controls included serum alone without bacteria, incubated and handled in parallel with the test samples. The serum-sensitive E. coli strain was used as a positive control.
Consumption of C3, C5, and C9. From 10' to 109 bacterial CFU from 24-h C.fetus cultures were incubated at 370C with NHS for 120 min on a rotater. At designated times, an aliquot of the reaction mixture was withdrawn, immediately plunged into an ice bath, and the bacterial cells pelleted by centrifugation at 12,000gfor2 min, and each supernatant quick-frozen at -70'C. Consumption of hemolytic C3, C5, and C9 from the supernatant was measured by using published procedures (15) . The percent consumption in experimental samples was determined relative to control serum samples without bacteria, incubated in parallel with the test samples.
Purification and radiolabeling ofcomplement components. C3 and C9 were purified from fresh human plasma by using modifications of the procedure published by Hammer (15, 16 ). Both preparations gave single bands on SDS-PAGE and a single line on double diffusion when tested with antisera to whole human serum. The specific hemolytic activities ofthe purified preparations were as follows: for C3, 117 U/ag (serum 1.11 X 105 U/ml); and for C9, 746 U/ag (serum 4 X I04 U/ml).
C3 and C9 were radiolabeled with '25INa by using iodobeads to specific activities of4.7 X 10' cpm/gg for C3 and 9.3 X 10' cpm/gg for C9. For some experiments, C3 was labeled with NaB 3H4 by reductive methylation to a specific activity of 2.8 X 106 cpm/gg.
Binding of C3 and C9. Binding of C3 and C9 to the bacterial surface was measured as described previously (15) . Briefly, mixtures of serum and bacteria were prepared as described above for the serum bactericidal assay, except that the bacterial inoculum was raised to 10' to 109 CFU/ml, and that either 12I-C3, [3HJC3, or 125I.C9 was added to the mixture. Samples were incubated at 370C. At designated intervals, 200-Ml samples-were removed and added to microcentrifuge tubes containing 1 ml of cold HBSS, and the tubes were centrifuged for 5 min at 12,500 g. The supernatants were aspirated completely, and the pellets were counted in a gamma counter. For determining binding when [3H]C3 was used, pellets were boiled in 1% SDS for 5 min, scintillation fluid (Opti-fluor, Packard Instrument Co., Downers Grove, IL) added, and counted in a beta counter. Controls for nonspecific binding were bacteria that were incubated in serum previously heated for 30 min at 560C (HINHS) to block complement activation. Molecules ofC3 and C9 bound to the bacterial surface were calculated as described previously (15) . l21J_9 was eluted from the bacterial cells by repeated washing as described (17) except that Medium 199 was used. The molecular form of C3 bound to the test bacteria was determined after release ofcovalently bound C3 from acceptor molecules by hydroxylamine cleavage, followed by SDS-PAGE and autoradiography as described (18, 19 Preparation of human PMN. 20 ml of peripheral venous blood from one ofseveral healthy donors was collected in a syringe with 6 ml of dextran (6% wt/vol) in 0.9% saline with 300 U of heparin and erythrocytes sedimented at 370C for 1 h essentially as described (20 Phagocytosis. Phagocytic studies were based on the percent association of 32P-labeled C. fetus cells with PMN. Bacteria were grown in brucella broth with 500 MCi of32P (New England Nuclear, Boston MA) for 18 h at 370C in a microaerobic atmosphere. The cells were washed twice in SDW and the pellet resuspended in Hank's gel to a concentration of 108/ml. The phagocytosis assay was done at 370C for 60 min according to the methods of Gupta et al. (20) . The reaction mixture contained equal (0.25 ml) parts ofthe serum used for opsonization, the bacteria, the PMN in Hank's gel at a final concentration of 107/ml and Hank's gel alone. Experiments were done using the following serum sources: NHS, HINHS, no serum, or immune serum to either 82-40 LP or 82-40 HP as described above. As a control, no PMN were used in a parallel assay. The reaction was started by the addition of the PMN suspension and stopped by immersion into ice water. The PMN were separated from the bulk of the noningested bacteria by centrifugation at 436 g for 5 min, washed free of adhering bacteria, and the cell-associated radioactivity was determined. Viable bacterial counts of the original inoculum, supernatant, and pellet were determined, by plating serial dilutions of each in duplicate.
Electron microscopy. Electron microscopy was performed on preparations of PMN after the phagocytosis experiments according to the methods of Iwata et al. (22) . After being washed twice in HBSS, the pellet was fixed for 2 h in 2% (vol/vol) glutaraldehyde buffered in 0.1 M phosphate (pH 7.2), washed in the same buffer, and postfixed in 1% (wt/vol) osmium tetroxide. The pellet was dehydrated and thin sections and grids were obtained as described (22) and resolved on a Philips 300 electron microscope.
Chemiluminescence. Bacteria were preopsonized as in the PMN killing assays except in 200 ul of serum. PMN were harvested by sedimentation in Hetastarch followed by a Percoll gradient as previously described (23, 24) , and used at a final concentration in HBSS of 106/ml. The reaction mixture, in polystyrene tubes (Sarstedt No. 55.484, Sarstedt, Princeton, NJ) with 2 X 5-mm microstir bars, consisted of 20 Mul HINHS, 20 Mll 1 mM luminol (5-amino-2,3-dihydro-1,4-phthalazinedione [Sigma Chemical Co., St. Louis, MO]), 20 Ml PMN, 50 Ml HBSS, and 100 M1 of the preopsonized bacteria. Assays were performed at 37°C using a Picolite Luminometer (Packard Instrument Co.) with 15-s readings every 4 min for 1 h. Calculations were standardized to counts/PMN cell per min as described (24) .
Results
Effect of encapsulation on serum susceptibility of Campylobacterfetus. To investigate the role of encapsulation on serum susceptibility of C. fetus, the 100,000-mol wt surface protein containing strains and their spontaneously mutated 100,000-mol wt protein-lacking daughter strains ( Fig. 1) were incubated in pooled NHS. All strains were LPS serotype A. Confirming our earlier report (7), the encapsulated C. fetus strains 82-40 LP and 23D were resistant to killing by 10% NHS whereas their unencapsulated spontaneous mutant strains, 82-40 HP and 23B, were sensitive (Table I) . As previously reported (6, 7), neither encapsulated strains was killed in the presence of 10% homologous immune rabbit serum. The Campylobacter strains of other LPS serotypes and lacking the 100,000-mol wt proteins were serum-sensitive (Table I) .
Complement utilization by serum-resistant and serum-sen- sitive Campylobacter strains. To understand the mechanism for serum-resistance by C.fetus we initially addressed the question ofwhether a serum-resistant C. fetus strain was capable of consuming hemolytic complement activity. Campylobacter strains or a known serum-sensitive E. coli strain were incubated with NHS and residual CH50 activity assessed (Table II) . After 30 min of incubation, two serum-sensitive C. jejuni strains, the serum-sensitive E. coli strain, and the serum-resistant C. fetus strain produced similar consumption of CHs5 activity and after 60 min, activity was below the lower limit of detection. Thus, the serum-resistant C. fetus strain consumed total hemolytic complement to a similar extent as did the serum-sensitive E. coli and C. jejuni strains.
C3 consumption by Campylobacter cells. To specifically address the question ofthe role ofthe capsule in serum-resistance of C. fetus and to begin an analysis ofthe location ofthe block in complement-mediated lysis, we next incubated the two serum-resistant encapsulated C. fetus strains, the serum-sensi- (6) . For specific results, see Table I . * Limit of detection.
Not done. tive unencapsulated C. fetus strains, and a (control) serumsensitive C. jejuni strain with pooled NHS and measured C3 consumption (Table III) . By 120 min, incubation with the bacterial cells produced consumption of41-57% ofC3 activity compared with a control serum without bacteria incubated. The serum-resistant strains consumed the same amount of C3 as did the serum-sensitive strains, a reproducible finding in three separate experiments. From these studies we concluded that differences in C3 consumption could not explain the marked differences in serum susceptibility of the strains. CS and C9 consumption. To determine whether serum resistance was mediated at a later point in the complement cascade, we next examined consumption of C5 and C9, two complement components associated with the bacteriolytic terminal membrane attack complex. For C. fetus strain 23D consumption of both C5 and C9 were markedly impaired when compared with strain 23B (Fig. 2) ; the extent of the defect in consumption for strain 23D was parallel for C5 and fetus-immune rabbit serum produced more rapid consumption of C9 by C. fetus than did normal serum but did not significantly increase total consumption at 60 minutes.
C9 binding. To determine if the differences in terminal component consumption were reflected in differences in COb-9 binding, we measured deposition ofC9 on sensitive and resistant strains. In the presence of normal serum, specific C9 deposition on serum sensitive, unencapsulated strains, was rapid and extensive, peaking by 30-60 min. The amount ofC9 bound after 30 minutes was 3-to 10-fold higher than on the serum-resistant, encapsulated strains. Results are shown in Fig. 3 C3 binding. Although consumption of C3 by the encapsulated strains was equivalent to consumption by the unencapsulated strains, the limited C5 and C9 consumption and C9 binding on the former group suggested that formation of the C5 convertase on the surface of these cells was defective. To test this possibility, and because C3 is an obligatory component of the C5 convertase, we compared binding of either 125i-or 3H-labeled C3 to the encapsulated and unencapsulated strains. For both encapsulated strains, C3 binding in the presence of NHS was markedly impaired compared with the unencapsulated strains. Results comparing binding to strains 23B and 23D are shown in Fig. 4 . Although incubation with immune serum permitted a small increase in C3 binding to encapsulated strain 82-40 LP, it did not correct the substantial defect in comparison to the unencapsulated strain (Fig. 5 ).
Molecular form of bound C3. The biological activity of bound C3 depends on the molecular configuration of the bound fragment. Although the previous work showed that there was a marked quantitative difference in C3 binding to the encapsulated and unencapsulated strains, we next considered whether there was a qualitative difference as well. To accomplish this, we examined the form of C3 deposited on the encapsulated and unencapsulated strains, in this case, 23D and 23B. To determine which C3 components bound to the cell surface, bacterial cells that had been incubated with '25I-C3 were washed, treated with hydroxylamine to release covalently bound C3, radioactive counts in the supernatants equalized and proteins resolved by SDS-PAGE and autoradiography (Fig. 6 ). On 23B, the alpha prime chain fragment (1 15 ,000 mol wt) indicative of C3b predominated over the alpha chain fragment (67,000 mol wt) indicative of the hemolytically inactive cleavage product, iC3b. In contrast, for strain 23D, more iC3b is present as reflected by a relatively greater proportion of label present in the 67,000-mol wt fraction. In addition, a large C3b and iC3b were found on the surface of strain 23B with the hemolytically active C3b residues predominating. Although the amount of C3 bound to 23D was significantly less than to 23B (Fig. 4) Influence ofopsonin source on bactericidal activity ofPMN toward C. fetus strains. Since the amount and form of bound C3 influences its function as an opsonin, the following experiments were designed to provide answers to two basic questions: first, are PMN bactericidal to C. fetus strains, and second, how does the presence of the capsular protein affect this we found > 1-log,0 killing ofthis organism by 60 min, whereas no killing was observed in the absence of PMN, as expected, (Fig. 7 A) . Under identical assay conditions, we found that for the unencapsulated strain 82-40 HP opsonized with HINHS there was greater than 2-log10 killing in the presence of PMN but not in their absence (Fig. 7 B) , indicating that these organisms are readily killed by PMN. Since HINHS was used for these assays, these results show that complement activation is not necessary for opsonization ofthe unencapsulated strain. In contrast, the encapsulated strain, 82-40 LP, was not killed by PMN in the presence of HINHS or NHS (Fig. 7, C and D) . Preopsonization of this strain by immune serum permitted PMN killing in the presence of both intact (Fig. 7 E) and heat-inactivated serum (Fig. 7 F) , suggesting that specific antibody alone was sufficient for opsonization. protein (7) and lipopolysaccharide (1 1) (26); further, the extent ofthe chemiluminescence response has been used to measure bacterial phagocytosis by PMN (27) . Initial studies showed that in the presence of HINHS a ratio of 500 C. fetus 82-40 HP CFU per PMN provided maximal chemiluminescence response (Fig. 8 A) , and that results were nearly identical whether the bacteria were preopsonized or opsonized during incubation with the PMN (data not shown). However, there was minimal stimulation of the chemiluminescence response by C. fetus 82-40 LP cells in the presence of HINHS, at the same 500:1 ratio (Fig. 8 B) . In a subsequent assay, stimulation of chemiluminescence in the presence of HINHS again was negligible whereas a significantly greater response was shown in the presence of immune serum (Fig. 9) . Preopsonization with 1.25-100% immune serum produced maximal chemiluminescence response, but absorption of the immune serum six times with the homologous encapsulated strain ablated virtually all of the increment in chemiluminescence response above the baseline produced in the presence of HINHS (data not shown), suggesting that specific antibody mediated the enhanced chemiluminescence response of immune serum. These experiments indicate that in the absence of specific antibody encapsulated C. fetus cells are not taken up by PMN or that they have bypassed chemiluminescence-producing mechanisms.
Uptake of C. fetus strains by PMN. To further clarify the reason for the poor chemiluminescence response, we then examined the association of radiolabeled bacteria with human PMN. As expected, at a ratio of bacteria:PMN of 10:1 using 32P-labeled Staphylococcus aureus 502A, opsonization with NHS permitted significantly greater cell-association than for nonopsonized bacteria. Using this same assay for 32P-labeled C. fetus cells opsonized with HINHS, in the absence of PMN, for both strains essentially no counts were present in the pellet produced by low-speed centrifugation, as expected ( To determine the nature of this association, we performed electron microscopy on mixtures of the encapsulated and unencapsulated bacteria opsonized with HINHS. Within 5 min, virtually all of the cells ofthe unencapsulated strain were seen within phagocytic vacuoles inside the PMN (Fig. 11 A) . In contrast, essentially all of the encapsulated organisms were extracellular ( Fig. 11 B) ; only rare intracellular organisms were seen. As indicated by the chemiluminescent, radiolabel uptake and electron microscopic studies, the mechanism by which the encapsulated strains resist PMN killing appears to be lack of phagocytosis. strains. Our data are consistent with the hypothesis that failure of C3b binding to the encapsulated strain is the central mechanism for serum resistance, although the mechanism for C3 consumption without binding to these organisms is presently unknown. Binding of C3 but with rapid release is one possible mechanism; however, binding determinations done after only 5 min of incubation do not support this hypothesis. The capsular protein may have protease activity for C3 or C3 fragments but we could find no evidence for this. Alternatively, the capsule may preclude covalent attachment of C3 to the bacterial surface which would not permit amplification by the alternative pathway (33) . In any event, the mechanism ofserum-resistance of encapsulated C. fetus appears to be novel and differs from those described for smooth Enterobacteriaceae (15), or serum-resistant gonococci (34, 35) . For those organisms, C3 binding and C5b-9 generation are efficient, but for a variety of reasons (18, 34) the terminal membrane attack complex fails to insert into vital cell membrane structures. The exact mechanisms involved in the novel form ofcomplementresistance by encapsulated C. fetus cells deserve further examination.
Encapsulated C. fetus strains resist PMN killing except in the presence of immune serum, confirming and extending the observations of McCoy et al. (8) . Antibody to capsule per se is not necessary, as killing occurs in the presence of antibody to other Campylobacter strains which lack the S-proteins but which share other surface determinants (7, 11, 25 electron microscopy. Results of all experiments were consistent with the hypothesis that resistance to killing is due to the ability of encapsulated strains to resist phagocytosis, but if properly opsonized, these organisms are readily killed. The parallel anti-opsonic properties of capsules of other serum-resistant bacteria including pneumococci (36) , and Vibrio vulnificus (37) have been well described. Not surprisingly, unencapsulated C. fetus cells which share core LPS antigens with other gram-negative organisms (38) , are readily phagocytosed and killed by PMN. The failure of encapsulated C. fetus strains to be killed by PMN in the presence of NHS also is consistant with defective C3 binding. iC3b is a more important opsonin ofencapsulated pneumococci than is C3b (39) . Although iC3b is the predominant form deposited on encapsulated C. fetus strains, the very small amounts of C3 derivatives deposited in toto are apparently unable to stimulate phagocytosis via either the CR1 or CR3 receptors. That heat-inactivated immune serum is fully opsonic whereas NHS is not, suggests that phagocytosis is occurring via the Fc but not the C3 receptors of the PMN (40) . Thus, encapsulation potentially provides important advantages for C. fetus cells in mammalian hosts. The host may destroy unencapsulated C. fetus organisms by either serum or phagocytic cells, but must wait for development of specific antibodies to permit destruction of these encapsulated organisms by phagocytic cells. This model helps explain why nearly all C. fetus infections of humans are caused by encapsulated strains (7) . Conservation of amino acid composition, antigenicity, and amino-terminal sequence for the S-layer proteins derived from a variety of strains (41) further indicates the biological relevance of these molecules.
